|
25 February 2002. The Washington Post reported last Friday that a dozen
patients in the suspended trial of the Aβ vaccine AN-1792 have now fallen
ill with cerebral inflammation. The newspaper also reported, and Elan
company spokesman Max Gershenoff confirmed to Alzforum, that some of those
additional cases turned up outside of France. This is relevant because the
initial four cases in this joint U.S.-European trial were all in France, which
led the company to suggest that the problem may not have been due to the
trial vaccine.
Gershenoff refuted the Journal's assertion that the trial had now been
halted. The trial remains temporarily suspended, though this distinction
appears increasingly semantic. The company refuses further comment pending a
review by an independent safety monitoring board. See our live
discussion on AD immunotherapy.-Gabrielle Stroebel.
|
Home
